CLINICIAN REVIEWEDEVIDENCE-BASED

Tuberculosis

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. It most often affects the lungs, but it can involve almost any organ. TB spreads through the air from a person with infectious pulmonary or laryngeal disease and is both preventable and curable.

At a glance

Quick facts

Condition snapshot
Category
Bacterial infectious disease
Main route
Airborne transmission
Most common site
Lungs
Common symptoms
Cough, fever, weight loss, night sweats
Diagnosis
WHO-recommended rapid tests
Treatment
Combination anti-TB medicines
Medically reviewed

Dr. Fitsum Admasu Tinsae

General Medicine, Public Health, Digital Health

Reviewed for clinical accuracy, clarity and practical public-health context.

Names & terminology

Names and related terms

Medical name
Tuberculosis (TB).
TB infection
Infection without clinical TB disease; people with TB infection are not contagious.
TB disease
Active clinical disease caused by M. tuberculosis, pulmonary or extrapulmonary.
Drug-resistant TB
TB caused by organisms resistant to one or more key anti-TB medicines; regimen selection requires resistance testing and guideline-based care.

Clinical reference

Clinical profile

Key facts
CauseMycobacterium tuberculosisA bacterial infection transmitted through airborne particles.
Main siteLungsPulmonary TB is the commonest form and the main source of person-to-person transmission.
Other sitesLymph nodes, CNS, bones, abdomen, kidneysExtrapulmonary TB is especially important in children and immunocompromised patients.
DiagnosisRapid molecular testing + microbiologyWHO recommends rapid diagnostic tests as initial tests for people with signs or symptoms of TB.
TreatmentMulti-drug combination therapyRegimen and duration depend on drug susceptibility, disease site, age and prior treatment.
PreventionCase finding, TPT, infection control, BCGPrevention combines treatment of infectious disease with protection of high-risk contacts.

Overview

TB develops when infection with Mycobacterium tuberculosis progresses to disease. People with TB infection have no symptoms and are not contagious, but some later develop TB disease, especially when immunity is weakened. [1] [4]

WHO estimated that 10.7 million people developed TB in 2024 and 1.23 million died from the disease, including 150,000 people with HIV. TB remains the leading cause of death from a single infectious agent globally. [1]

Symptoms and warning signs

Pulmonary TB commonly causes a prolonged cough, chest pain, fever, night sweats, fatigue, loss of appetite and weight loss; coughing up blood can occur. Extrapulmonary TB causes symptoms related to the affected organ and may be more difficult to recognize. [1]

1 expert note

I do not assume that every patient with TB will have a prolonged cough. Extrapulmonary disease can present outside the respiratory system, and people living with HIV may have less typical presentations, so the threshold for evaluation should reflect the whole clinical context.

SYMPTOM MATRIX

TB can be subtle for months — or severe when it involves the CNS, lungs or multiple organs

Symptoms depend on disease site, immune status and age.

Airborne infection
Common pulmonary features
  • Prolonged cough
  • Fever
  • Night sweats
  • Weight loss
  • Fatigue or reduced appetite
Extrapulmonary clues
  • Enlarged lymph nodes
  • Persistent back or joint pain
  • Abdominal symptoms
  • Headache or neurologic symptoms
  • Pleural or pericardial disease
Urgent / severe patterns
  • Severe breathlessness
  • Coughing significant blood
  • Confusion or meningitis symptoms
  • Severe illness in a young child
  • Advanced HIV with systemic deterioration

Severe TB or TB meningitis requires urgent specialist evaluation and treatment.

Diagnosis

WHO recommends rapid diagnostic tests as initial tests for people with signs or symptoms of TB. Molecular tests can detect M. tuberculosis and, for some assays, resistance to important medicines much faster than conventional culture. [1] [2]

Sputum is commonly tested in pulmonary TB, but specimen choice depends on age and disease site. Chest radiography can support triage and diagnosis but does not establish TB by itself. Tests for TB infection identify immune sensitization and are mainly used to determine who may benefit from preventive treatment after active disease has been excluded. [2] [4]

Diagnostic pathway

Confirm TB and detect resistance early

The diagnostic pathway should identify both the organism and the treatment-relevant resistance pattern.

Rapid diagnostics
1Recognize a compatible syndromeAssess cough, fever, weight loss, exposure, HIV status and extrapulmonary symptoms.
2Obtain the right specimenUse sputum or a site-specific sample according to age and suspected disease location.
3Use a WHO-recommended rapid testDetect M. tuberculosis and key resistance markers as early as possible.
4Stage disease and comorbidityAssess severity, HIV, diabetes, nutrition, pregnancy and other factors that affect care.
Initial testRapid molecular testWHO-recommended where available
ResistanceMolecular / phenotypic DSTguides regimen

A normal or non-specific chest X-ray does not exclude TB, especially in children or immunocompromised patients.

Drug-resistant tuberculosis

Drug-resistant TB can be transmitted directly or emerge when treatment is ineffective or incomplete. Rapid detection matters because standard drug-susceptible regimens may fail. WHO treatment recommendations increasingly use shorter all-oral regimens for eligible drug-resistant disease, selected according to resistance pattern and clinical context. [2] [3]

Treatment and management

Drug-susceptible TB is treated with a combination of anti-TB medicines. Depending on eligibility and national guidance, treatment may use a standard six-month regimen or a shorter WHO-recommended regimen. Drug-resistant TB requires different combinations based on resistance results, prior exposure and disease severity. [1] [3]

Patient-centred support is part of treatment: clinicians monitor response, adverse effects and adherence and address nutrition, mental health, social barriers and comorbid conditions. People living with HIV need coordinated TB and antiretroviral care, including attention to drug interactions and timing. [1] [3]

1 expert note

I emphasize completing the full TB regimen, attending scheduled follow-up and maintaining adequate nutrition. These practical points support recovery and reduce avoidable treatment failure and drug resistance.

Treatment & care hub

Effective TB care combines the right regimen with support to complete it

Treatment failure and ongoing transmission become more likely when resistance or adherence barriers are missed.

TB care
Drug-susceptible TBCurative

Combination therapy

Use a WHO-recommended multi-drug regimen for the full planned duration.

Drug-resistant TBResistance-guided

Use an appropriate all-oral regimen

Rapid resistance testing helps select shorter or longer regimens according to eligibility and resistance.

HIV / comorbidityIntegrated

Coordinate care

Treat TB alongside HIV, diabetes, undernutrition and other clinically important conditions.

Adherence supportEssential

Reduce treatment interruption

Counselling, adverse-effect management and social support improve the chance of completing curative treatment.

National TB programmes adapt WHO recommendations to local medicines, diagnostics and resistance patterns.

Prevention and TB infection

Prevention includes early diagnosis and effective treatment of infectious TB, ventilation and respiratory protection in higher-risk settings, contact investigation, BCG vaccination in national programmes and TB preventive treatment (TPT) for eligible people at high risk of progression from infection to disease. WHO specifically prioritizes people living with HIV, household contacts and other risk groups for TPT. [1] [4]

1 expert note

Ventilation is a practical prevention measure I discuss in crowded indoor settings because transmission risk rises with close, prolonged exposure to infectious pulmonary TB in poorly ventilated spaces.

TB in African health systems

TB and HIV remain closely linked in many African countries. Nigeria and the Democratic Republic of the Congo are among the eight countries that together accounted for about two thirds of global TB cases in 2024. Delayed diagnosis, undernutrition, HIV, diabetes and treatment access can all influence individual and community outcomes. [1]

Epidemiology

Tuberculosis statistics

Disease statistics

Estimated new or recurrent TB episodes10.7 million new cases

Worldwide, 2024

All ages; all forms of TB

Rounded 2025 WHO report estimate.

Source [2] ↗

TB incidence131 per 100,000 people (crude)

Worldwide, 2024

All ages; all forms of TB

Crude population rate from the 2025 WHO report.

Source [1] ↗

Estimated TB deaths1.23 million deaths

Worldwide, 2024

All ages; all forms of TB

Includes HIV-associated TB; rounded 2025 WHO report estimate.

Source [2] ↗

Estimated multidrug- or rifampicin-resistant TB390,000 new episodes

Worldwide, 2024

All ages; MDR/RR-TB

Subset of all TB episodes; not an additional burden to add to the total.

Source [2] ↗

Geographic statistics

TB incidence by countrycases per 100,000 people (crude), 2024

8 of 214 locations

South Africa389
Nigeria219
Kenya207
Botswana143
Ghana126
Mauritius13
United Kingdom9.7
United States3.2

One matched source series; source-defined locations. Bars scale to the displayed locations. Source [3] ↗

WHO model estimate; includes new and recurrent TB episodes.

About these figures

UI means uncertainty interval around a model estimate.

Uncertainty reported by the source
MeasureInterval or range
TB incidence95% UI 122–141 per 100,000

Country comparison

Dataset coverage: 214 countries and territories. Only locations in this matched source series are compared.

The country controls show how many locations are currently displayed. Choose All locations or search to explore the complete dataset.

Population: All ages; all forms of TB.

Rate base: Country population; all ages.

Country estimates come from the WHO database snapshot of 31 October 2026. Rounded headline and regional figures come from the 2025 report; differences between database vintages do not establish a trend.

TB incidence includes new and recurrent episodes. Total TB deaths include HIV-associated TB. Country rates are crude population rates.

The chart plots point estimates. Location-specific uncertainty intervals are available in the cited source.

Sources & methodology

Source 2

Method: WHO modelled global MDR/RR-TB burden, Global tuberculosis report 2025.

Age coverage: All ages.

Source 3

Method: WHO global TB database country burden model estimates, frozen 31 October 2026.

Common questions

Frequently asked questions

Reference content